Pembrolizumab + EP not cost effective vs EP as first-line treatment for SCLC in the USA
Keyword(s):
Keyword(s):
2018 ◽
Vol 25
(10)
◽
pp. 863-870
◽
Keyword(s):
2020 ◽
Vol 9
(2)
◽
pp. 93-102
Keyword(s):
2007 ◽
Vol 25
(18_suppl)
◽
pp. 6583-6583
2013 ◽
Vol 31
(15_suppl)
◽
pp. e19001-e19001
◽
Keyword(s):